GNE vs PCYO

GNE exhibits a strong deterministic health profile with a Piotroski F-Score of 8/9 and negligible debt (D/E 0.05), yet it is fundamentally overvalued. The current price of $13.79 significantly exceeds both the Graham Number ($6.99) and the growth-based Intrinsic Value ($2.03). While revenue growth remains robust at 23.6%, a sharp decline in earnings (-32% YoY) and a payout ratio exceeding 100% indicate an unsustainable dividend and deteriorating profitability. The combination of bearish technicals, insider selling, and consistent earnings misses suggests a high risk of price correction.

PCYO presents a contradictory financial profile characterized by a weak Piotroski F-Score (3/9) and a poor earnings track record, offset by an exceptionally clean balance sheet (Debt/Equity 0.05). While current growth metrics are strong, the massive spike in Forward P/E (123.11) compared to the trailing P/E (19.44) suggests a significant expected decline in future earnings. The stark discrepancy between the operating margin (5.09%) and profit margin (45.80%) indicates that recent profitability is likely driven by non-operating gains rather than core business efficiency. Consequently, the stock is valued near its Graham Number ($8.86) and Intrinsic Value ($16.81) midpoint, but lacks the fundamental quality to be bullish.